173 related articles for article (PubMed ID: 17537037)
1. A potential predictive marker for response to interferon in malignant melanoma.
Wild PJ; Meyer S; Landthaler M; Hofstaedter F; Bosserhoff AK
J Dtsch Dermatol Ges; 2007 Jun; 5(6):456-9. PubMed ID: 17537037
[TBL] [Abstract][Full Text] [Related]
2. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.
Meyer S; Wild PJ; Vogt T; Bataille F; Ehret C; Gantner S; Landthaler M; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
Exp Dermatol; 2010 Aug; 19(8):e251-7. PubMed ID: 20500769
[TBL] [Abstract][Full Text] [Related]
3. Tissue microarray analysis of methylthioadenosine phosphorylase protein expression in melanocytic skin tumors.
Wild PJ; Meyer S; Bataille F; Woenckhaus M; Ameres M; Vogt T; Landthaler M; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
Arch Dermatol; 2006 Apr; 142(4):471-6. PubMed ID: 16618867
[TBL] [Abstract][Full Text] [Related]
4. Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma.
Behrmann I; Wallner S; Komyod W; Heinrich PC; Schuierer M; Buettner R; Bosserhoff AK
Am J Pathol; 2003 Aug; 163(2):683-90. PubMed ID: 12875987
[TBL] [Abstract][Full Text] [Related]
5. Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma.
Hellerbrand C; Mühlbauer M; Wallner S; Schuierer M; Behrmann I; Bataille F; Weiss T; Schölmerich J; Bosserhoff AK
Carcinogenesis; 2006 Jan; 27(1):64-72. PubMed ID: 16081515
[TBL] [Abstract][Full Text] [Related]
6. Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy.
Chen ZH; Zhang H; Savarese TM
Cancer Res; 1996 Mar; 56(5):1083-90. PubMed ID: 8640765
[TBL] [Abstract][Full Text] [Related]
7. Methylthioadenosine phosphorylase deficiency in Japanese osteosarcoma patients.
Miyazaki S; Nishioka J; Shiraishi T; Matsumine A; Uchida A; Nobori T
Int J Oncol; 2007 Nov; 31(5):1069-76. PubMed ID: 17912432
[TBL] [Abstract][Full Text] [Related]
8. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy.
Marcé S; Balagué O; Colomo L; Martinez A; Höller S; Villamor N; Bosch F; Ott G; Rosenwald A; Leoni L; Esteller M; Fraga MF; Montserrat E; Colomer D; Campo E
Clin Cancer Res; 2006 Jun; 12(12):3754-61. PubMed ID: 16778103
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of methylthioadenosin phosphorylase by homozygous deletion in gastric carcinoma.
Kim J; Kim MA; Min SY; Jee CD; Lee HE; Kim WH
Genes Chromosomes Cancer; 2011 Jun; 50(6):421-33. PubMed ID: 21412930
[TBL] [Abstract][Full Text] [Related]
10. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells.
Hori H; Tran P; Carrera CJ; Hori Y; Rosenbach MD; Carson DA; Nobori T
Cancer Res; 1996 Dec; 56(24):5653-8. PubMed ID: 8971171
[TBL] [Abstract][Full Text] [Related]
11. Lack of STAT 1 phosphorylation at TYR 701 by IFNgamma correlates with disease outcome in melanoma patients.
Boudny V; Dusek L; Adámková L; Chumchalová J; Kocak I; Fait V; Lauerová L; Krejcí E; Kovarík J
Neoplasma; 2005; 52(4):330-7. PubMed ID: 16059651
[TBL] [Abstract][Full Text] [Related]
12. Significantly decreased methylthioadenosine phosphorylase expression in malignant melanoma.
Gambichler T; Scola N; Bechara FG
Am J Dermatopathol; 2012 Oct; 34(7):777-9. PubMed ID: 23000879
[No Abstract] [Full Text] [Related]
13. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
Illei PB; Rusch VW; Zakowski MF; Ladanyi M
Clin Cancer Res; 2003 Jun; 9(6):2108-13. PubMed ID: 12796375
[TBL] [Abstract][Full Text] [Related]
14. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line.
Christopher SA; Diegelman P; Porter CW; Kruger WD
Cancer Res; 2002 Nov; 62(22):6639-44. PubMed ID: 12438261
[TBL] [Abstract][Full Text] [Related]
15. Predictors of response to interferon therapy.
Gogas H; Kirkwood JM
Curr Opin Oncol; 2009 Mar; 21(2):138-43. PubMed ID: 19532015
[TBL] [Abstract][Full Text] [Related]
16. [Interferon: therapy in patients with cutaneous malignant melanoma in adjuvant setting].
Wcisło G; Szczylik C
Pol Merkur Lekarski; 2003 Jul; 15(85):5-8. PubMed ID: 14593950
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvant interferon treatment of melanoma].
Török L
Magy Onkol; 2003; 47(1):105-7. PubMed ID: 12704462
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of 5'-deoxy-5'-methylthioadenosine in melanoma cells by liquid chromatography-stable isotope ratio tandem mass spectrometry.
Stevens AP; Dettmer K; Wallner S; Bosserhoff AK; Oefner PJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Dec; 876(1):123-8. PubMed ID: 18996776
[TBL] [Abstract][Full Text] [Related]
19. Interferon (IFN) for malignant melanoma unmasking an autoimmune hepatitis.
Lebiedz P; August C; Domschke W; Schmidt HH
Eur J Intern Med; 2009 Jan; 20(1):e3-4. PubMed ID: 19237078
[No Abstract] [Full Text] [Related]
20. Methylthioadenosine phosphorylase as target for chemoselective treatment of T-cell acute lymphoblastic leukemic cells.
Efferth T; Miyachi H; Drexler HG; Gebhart E
Blood Cells Mol Dis; 2002; 28(1):47-56. PubMed ID: 11987241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
